ReviewIranian journal of biotechnology2025
Exploring the Therapeutic Potential: Antisense RNA Delivery Via Bacteriophage Platform.
Review in Iranian journal of biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Advancements in nucleic acid therapeutics have opened new avenues for treating genetic diseases, with antisense oligonucleotides (ASOs) such as antisense RNA (as RNA) emerging as promising candidates. RNA medicine, targeting various RNA molecules, offers potential therapeutic interventions. RNA-based therapeutics encounter challenges like stability, delivery, and off-target effects. Advances in delivery systems, such as lipid and polymeric nanoparticles and virus-like particles, offer solutions to enhance efficacy. This review explores the mechanisms and applications of RNA therapeutics, focusing on antisense oligonucleotides. Several platforms like lipid nanoparticles, polymeric nanoparticles, cell-penetrating peptides, exosomes, polyplexes, and virus-like particles (VLPs) for antisense RNA delivery are utilized to overcome challenges such as RNA stability and intracellular delivery. The potential of bacteriophages and VLPs as versatile delivery systems for RNA therapeutics targeting bacterial infections, biofilm eradication, cancer therapy, and viral infections is explored. Utilizing bacteriophages for targeted antisense RNA delivery improves therapeutic outcomes. Bacteriophage systems are advantageous due to ease of development, large cargo capacity, ability to carry non-DNA payloads, and relative safety, making them effective nanocarriers. The review also highlights FDA-approved ASO drugs and CRISPR-derived approaches for antibacterial and antiviral therapy. Through an in-depth analysis of platforms, mechanisms, and applications, this review provides insights into the expanding landscape of RNA therapeutics and their clinical implications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.